336 related articles for article (PubMed ID: 32057199)
21. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
22. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
[TBL] [Abstract][Full Text] [Related]
23. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
24. Predicting disability worsening in relapsing and progressive multiple sclerosis.
Simmons SB; Schippling S; Giovannoni G; Ontaneda D
Curr Opin Neurol; 2021 Jun; 34(3):312-321. PubMed ID: 33709974
[TBL] [Abstract][Full Text] [Related]
25. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
[TBL] [Abstract][Full Text] [Related]
26. Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM/TSP) and multiple sclerosis (MS).
Azodi S; Nair G; Enose-Akahata Y; Charlip E; Vellucci A; Cortese I; Dwyer J; Billioux BJ; Thomas C; Ohayon J; Reich DS; Jacobson S
Ann Neurol; 2017 Nov; 82(5):719-728. PubMed ID: 29024167
[TBL] [Abstract][Full Text] [Related]
27. Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
Sechi E; Messina S; Keegan BM; Buciuc M; Pittock SJ; Kantarci OH; Weinshenker BG; Flanagan EP
Mult Scler; 2021 Apr; 27(5):667-673. PubMed ID: 32552535
[TBL] [Abstract][Full Text] [Related]
28. Progressive Multiple Sclerosis.
Ontaneda D
Continuum (Minneap Minn); 2019 Jun; 25(3):736-752. PubMed ID: 31162314
[TBL] [Abstract][Full Text] [Related]
29. Contribution of new and chronic cortical lesions to disability accrual in multiple sclerosis.
Beck ES; Mullins WA; Dos Santos Silva J; Filippini S; Parvathaneni P; Maranzano J; Morrison M; Suto DJ; Donnay C; Dieckhaus H; Luciano NJ; Sharma K; Gaitán MI; Liu J; de Zwart JA; van Gelderen P; Cortese I; Narayanan S; Duyn JH; Nair G; Sati P; Reich DS
Brain Commun; 2024; 6(3):fcae158. PubMed ID: 38818331
[TBL] [Abstract][Full Text] [Related]
30. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
[TBL] [Abstract][Full Text] [Related]
31. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
[TBL] [Abstract][Full Text] [Related]
32. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
[TBL] [Abstract][Full Text] [Related]
33. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
34. Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.
Tanaka K; Kujuro Y; Suzuki S; Tanahashi N; Hamada J; Nogawa S; Suzuki N
Intern Med; 2005 Jun; 44(6):560-6. PubMed ID: 16020880
[TBL] [Abstract][Full Text] [Related]
35. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
36. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
[TBL] [Abstract][Full Text] [Related]
37. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
38. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
[TBL] [Abstract][Full Text] [Related]
39. Silent progression in disease activity-free relapsing multiple sclerosis.
; Cree BAC; Hollenbach JA; Bove R; Kirkish G; Sacco S; Caverzasi E; Bischof A; Gundel T; Zhu AH; Papinutto N; Stern WA; Bevan C; Romeo A; Goodin DS; Gelfand JM; Graves J; Green AJ; Wilson MR; Zamvil SS; Zhao C; Gomez R; Ragan NR; Rush GQ; Barba P; Santaniello A; Baranzini SE; Oksenberg JR; Henry RG; Hauser SL
Ann Neurol; 2019 May; 85(5):653-666. PubMed ID: 30851128
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
Lauerer M; McGinnis J; Bussas M; El Husseini M; Pongratz V; Engl C; Wuschek A; Berthele A; Riederer I; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):37-43. PubMed ID: 37495267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
